Coadministration with raltegravir (400 mg twice daily) increased raltegravir Cmax, AUC and Cmin by 22%, 20% and 13%, respectively. The increase in raltegravir exposures may be due to UGT1A1 inhibition by paritaprevir and ombitasvir. No clinically relevant changes in dasabuvir, paritaprevir and ombitasvir exposures (based on comparison with historical data) were observed during co-administration. No dose adjustment is necessary.

Coadministration of ombitasvir/paritaprevir/ritonavir ± dasabuvir with raltegravir (n=42) was studied in a retrospective observational study in co-infected HIV and HCV patients. There was no significant effect on raltegravir Ctrough, however the effect on ombitasvir, paritaprevir, ritonavir or dasabuvir was not studied.